PHASE I CLINICAL TRIAL OF PEPOSERTIB PLUS RADIOTHERAPY IN ADULTS WITH NEWLY-DIAGNOSED MGMT-UNMETHYLATED GLIOBLASTOMA

被引：0

作者：

Majd, Nazanin ^{[1
]}

Liu, John ^{[2
]}

Yeboa, Nana ^{[1
]}

Wang, Shuqi ^{[1
]}

Weathers, Shiao-Pei ^{[1
]}

Yuan, Ying ^{[1
]}

Gachimova, Evguenia ^{[1
]}

Wathoo, Chetna ^{[1
]}

Kamiya-Matsuoka, Carlos ^{[1
]}

O'Brien, Barbara ^{[1
]}

Aaroe, Ashley ^{[1
]}

Patel, Chirag ^{[1
]}

Patel, Anuj ^{[1
]}

Dagher, Samir ^{[1
]}

Wintermark, Max ^{[1
]}

Ferguson, Sherise ^{[1
]}

Puduvalli, Vinay ^{[1
]}

Raleigh, David ^{[2
]}

de Groot, John ^{[2
]}

机构：

[1] MD Anderson Canc Ctr, Houston, TX USA

[2] Univ Calif San Francisco, San Francisco, CA USA

来源：

NEURO-ONCOLOGY | 2024年 / 26卷

关键词：

D O I：

10.1093/neuonc/noae165.0461

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

DNAR-10

引用

页数：1

共 50 条

[21] A phase 0/2 'trigger' trial of pamiparib or olaparib plus radiotherapy in patients with newly-diagnosed or recurrent glioblastoma
Sanai, Nader
Chang, Yu-Wei
Jiang, Jun
Molloy, Jennifer
Pennington-Krygier, Chelsea
Harmon, Jocelyn
Hong, Amy
Wanebo, John
Kennedy, William
Garcia, Michael
Barani, Igor
Yoo, Wonsuk
Tovmasyan, Artak
Tien, An-Chi
Li, Jing
Mehta, Shwetal
CANCER RESEARCH, 2024, 84 (07)
[22] FINAL RESULTS OF THE MGMT UNMETHYLATED ARM OF PARADIGM-2: A PHASE I STUDY OF OLAPARIB AND RADIOTHERAPY IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
Derby, S. J.
Sweeting, L.
Shad, S.
Paterson, L.
Stobo, J.
Nowicki, S.
Williamson, A.
James, A.
Short, S. C.
McBain, C.
Herbert, C.
Powell, J.
Kelly, C.
Chalmers, A. J.
NEURO-ONCOLOGY, 2023, 25
[23] Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
Wei, Kuo-Chen
Hsu, Peng-Wei
Tsai, Hong-Chieh
Lin, Ya-Jui
Chen, Ko-Ting
Toh, Cheng-Hong
Huang, Hui-Lin
Jung, Shih-Ming
Tseng, Chen-Kan
Ke, Yu-Xiong
SCIENTIFIC REPORTS, 2021, 11 (01)
[24] Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study
Kuo-Chen Wei
Peng-Wei Hsu
Hong-Chieh Tsai
Ya-Jui Lin
Ko-Ting Chen
Cheng-Hong Toh
Hui-Lin Huang
Shih-Ming Jung
Chen-Kan Tseng
Yu-Xiong Ke
Scientific Reports, 11
[25] Phase 1 dose-finding study to evaluate safety and tolerability of CVGBM in patients with newly diagnosed and surgically resected MGMT-unmethylated glioblastoma.
Tabatabai, Ghazaleh
Von Baumgarten, Louisa
Van Den Bent, Martin J.
Burger, Michael C.
Freres, Pierre
Glas, Martin
Hau, Peter
Herrlinger, Ulrich
Mildenberger, Iris
Neyns, Bart
Schafer, Henning Sebastian
Seidel, Clemens
Galot, Rachel
Wick, Antje
Falk, Martin H.
Chama, Laura Leticia de Freitas
Kelemen, Peter
Koch, Sven D.
Roche, Paula Romer
Gnad-Vogt, Senta Ulrike
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[26] GENOME-WIDE DNA METHYLATION PATTERNS IN VERTU: A RANDOMIZED PHASE II TRIAL OF VELIPARIB, RADIOTHERAPY AND TEMOZOLOMIDE IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA
Sim, Hao-Wen
Lwin, Zarnie
Barnes, Elizabeth
McDonald, Kerrie
Koh, Eng-Siew
Rosenthal, Mark
Foote, Matthew
Back, Michael
Wheeler, Helen
Buckland, Michael
Walsh, Kyle
Fisher, Lauren
Leonard, Robyn
Hall, Merryn
Ashley, David
Yip, Sonia
Simes, John
Sulman, Erik
Khasraw, Mustafa
NEURO-ONCOLOGY, 2022, 24 : 81 - 81
[27] FIRST IN HUMAN STUDY OF THE MRNA-BASED CANCER VACCINE CVGBM IN PATIENTS (PTS) WITH NEWLY-DIAGNOSED AND SURGICALLY RESECTED MGMT-UNMETHYLATED GLIOBLASTOMA (GBM): FIRST RESULTS FROM THE DOSE ESCALATION PHASE
Tabatabai, Ghazaleh
Freres, Pierre
Glas, Martin
Hau, Peter
von Baumgarten, Louisa
van den Bent, Martin
Burger, Michael C.
Seidel, Clemens
Herrlinger, Ulrich
Mildenberger, Iris
Neyns, Bart
Schafer, Henning
Wick, Antje
Falk, Martin
de Chama, Laura Leticia Freitas
Kelemen, Peter
Schwenke, Frauke
Koch, Sven D.
Roche, Paula Romer
Gnad-Vogt, Ulrike
NEURO-ONCOLOGY, 2024, 26
[28] NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Lassman, A. B.
Polley, M. C.
Iwamoto, F. M.
Sloan, A. E.
Wang, T. J. C.
Aldape, K. D.
Wefel, J. S.
Gondi, V.
Gutierrez, A. N.
Manasawala, M.
Gilbert, M. R.
Sulman, E. P.
Wolchok, J. D.
Greene, R. M.
Neil, E. C.
Lukas, R. V.
Goldlust, S. A.
Snuderl, M.
Dignam, J. J.
Won, M.
Movsas, B.
Mehta, M. P.
NEURO-ONCOLOGY, 2023, 25
[29] NRG ONCOLOGY STUDY BN007: RANDOMIZED PHASE II/III TRIAL OF IPILIMIUMAB (IPI) PLUS NIVOLUMAB (NIVO) VS. TEMOZOLOMIDE (TMZ) IN MGMT-UNMETHYLATED (UMGMT) NEWLY DIAGNOSED GLIOBLASTOMA (NGBM)
Lassman, Andrew
Polly, Mei-Yin
Iwamoto, Fabio
Sloan, Andrew
Wang, Tony
Aldape, Kenneth
Wefel, Jeffrey
Gondi, Vinai
Gutierrez, Alonson
Manasawala, Mohammed
Gilbert, Mark
Sulman, Erik
Wolchok, Jedd
Green, Richard
Neil, Elizabeth
Lukas, Rimas
Goldlust, Samuel
Snuderl, Matija
Dignam, James
Won, Minhee
Movsas, Benjamin
Mehta, Minesh
NEURO-ONCOLOGY, 2023, 25
[30] Anti-telomerase vaccine in patients with newly diagnosed, unmethylated MGMT glioblastoma: A phase II study
Carpentier, Antoine F.
Verlut, Clotilde
Ghiringhelli, Francois
Bronnimann, Charlotte
Ursu, Renata
Fumet, Jean David
Gherga, Elisabeta
Lefort, Felix
Belin, Catherine
Vernerey, Dewi
Hervieu, Alice
Laheurte, Caroline
Meurisse, Aurelia
Jacquin, Marion
Malfroy, Marine
Fagnoni-Legat, Christine
Lehmann-Che, Jacqueline
Boullerot, Laura
Cuzzubbo, Stefania
Adotevi, Olivier
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →